DIEBOLD NIXDORF, Inc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that DIEBOLD NIXDORF, Inc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.81B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $3.75B | Feb 12, 2026 |
| FY2023 | Dec 31, 2023 | $1.63B | Mar 8, 2024 |
| FY2023 | Aug 12, 2023 | $2.13B | Mar 8, 2024 |
| FY2025 | Aug 11, 2023 | $2.13B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $3.46B | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $3.91B | Mar 8, 2024 |
| FY2020 | Dec 31, 2020 | $1.11B | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | $995.20M | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | $890.50M | Mar 1, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $1.25B | Feb 28, 2018 |
| FY2017 | Sep 30, 2017 | $1.12B | Feb 28, 2018 |
| FY2017 | Jun 30, 2017 | $1.13B | Feb 28, 2018 |
| FY2017 | Mar 31, 2017 | $1.10B | Feb 28, 2018 |
| FY2017 | Dec 31, 2016 | $1.24B | Feb 28, 2018 |
| FY2017 | Sep 30, 2016 | $983.30M | Feb 28, 2018 |
| FY2017 | Jun 30, 2016 | $580.00M | Feb 28, 2018 |
| FY2017 | Mar 31, 2016 | $509.60M | Feb 28, 2018 |
| FY2016 | Dec 31, 2015 | $610.40M | Feb 24, 2017 |
| FY2016 | Sep 30, 2015 | $589.60M | Feb 24, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $961.20M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $920.00M | Feb 12, 2026 |
| FY2023 | Dec 31, 2023 | $353.00M | Mar 8, 2024 |
| FY2023 | Aug 12, 2023 | $520.00M | Mar 8, 2024 |
| FY2025 | Aug 11, 2023 | $520.00M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $757.30M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $1.04B | Mar 8, 2024 |
| FY2020 | Dec 31, 2020 | $276.50M | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | $284.10M | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | $247.60M | Mar 1, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $94.60M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | ($16.50M) | Feb 12, 2026 |
| FY2023 | Dec 31, 2023 | $17.80M | Mar 8, 2024 |
| FY2023 | Aug 12, 2023 | $1.36B | Mar 8, 2024 |
| FY2025 | Aug 11, 2023 | $1.36B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | ($581.40M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | ($78.80M) | Mar 8, 2024 |
| FY2020 | Dec 31, 2020 | ($51.20M) | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | ($101.40M) | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | ($23.70M) | Mar 1, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $242.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $182.10M | Feb 12, 2026 |
| FY2023 | Dec 31, 2023 | $92.40M | Mar 8, 2024 |
| FY2023 | Aug 12, 2023 | ($5.50M) | Mar 8, 2024 |
| FY2025 | Aug 11, 2023 | ($5.50M) | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | ($211.70M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $137.10M | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | $24.00M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | ($26.60M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2018 | ($325.60M) | Mar 1, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $86.70M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $93.60M | Feb 12, 2026 |
| FY2023 | Dec 31, 2023 | $34.40M | Mar 8, 2024 |
| FY2023 | Aug 12, 2023 | $62.30M | Mar 8, 2024 |
| FY2025 | Aug 11, 2023 | $62.30M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $120.70M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $126.30M | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | $133.40M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $147.10M | Mar 11, 2022 |
| FY2020 | Dec 31, 2018 | $157.40M | Mar 1, 2021 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $632.50M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $643.60M | Feb 12, 2026 |
| FY2023 | Dec 31, 2023 | $226.00M | Mar 8, 2024 |
| FY2023 | Aug 12, 2023 | $458.70M | Mar 8, 2024 |
| FY2025 | Aug 11, 2023 | $458.70M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $741.60M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $775.60M | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | $858.60M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $908.80M | Mar 11, 2022 |
| FY2020 | Dec 31, 2018 | $893.50M | Mar 1, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $300.70M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $149.20M | Feb 12, 2026 |
| FY2023 | Dec 31, 2023 | $162.40M | Mar 8, 2024 |
| FY2023 | Aug 12, 2023 | ($419.40M) | Mar 8, 2024 |
| FY2025 | Aug 11, 2023 | ($415.00M) | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | ($387.90M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $123.30M | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | $18.00M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $135.80M | Mar 11, 2022 |
| FY2020 | Dec 31, 2018 | ($104.10M) | Mar 1, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2010 | Dec 31, 2010 | $51.30M | Feb 22, 2011 |
| FY2010 | Dec 31, 2009 | $44.29M | Feb 22, 2011 |
| FY2010 | Dec 31, 2008 | $57.93M | Feb 22, 2011 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.85B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $3.54B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $4.16B | Feb 25, 2025 |
| FY2023 | Aug 12, 2023 | $4.18B | Mar 8, 2024 |
| FY2023 | Aug 11, 2023 | $4.18B | Mar 8, 2024 |
| FY2023 | Dec 31, 2022 | $3.07B | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $3.51B | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $3.66B | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $3.79B | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $4.28B | Feb 26, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.75B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $2.61B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $3.08B | Feb 25, 2025 |
| FY2023 | Aug 12, 2023 | $3.13B | Mar 8, 2024 |
| FY2023 | Dec 31, 2022 | $4.44B | Mar 8, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.10B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $929.80M | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $1.06B | Feb 25, 2025 |
| FY2023 | Aug 12, 2023 | $1.04B | Mar 8, 2024 |
| FY2023 | Dec 31, 2022 | ($1.38B) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($845.10M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($827.10M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($530.30M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($149.70M) | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $445.50M | Mar 1, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $642.40M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $586.40M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $612.30M | Feb 12, 2026 |
| FY2023 | Aug 12, 2023 | $621.00M | Mar 8, 2024 |
| FY2024 | Aug 11, 2023 | $616.60M | Feb 25, 2025 |
| FY2024 | Dec 31, 2022 | $702.30M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $743.60M | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | $800.40M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $764.00M | Mar 11, 2022 |
| FY2020 | Dec 31, 2018 | $798.20M | Mar 1, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $91.90M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | ($1.10M) | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $17.10M | Feb 25, 2025 |
| FY2023 | Aug 12, 2023 | $0 | Mar 8, 2024 |
| FY2023 | Dec 31, 2022 | ($1.41B) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($822.40M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($742.30M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($472.30M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($131.00M) | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $374.50M | Mar 1, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $368.90M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $296.20M | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $550.20M | Feb 25, 2025 |
| FY2023 | Aug 12, 2023 | $391.40M | Mar 8, 2024 |
| FY2024 | Aug 11, 2023 | $395.80M | Feb 25, 2025 |
| FY2024 | Dec 31, 2022 | $307.40M | Feb 25, 2025 |
| FY2017 | Dec 31, 2017 | $535.20M | Feb 28, 2018 |
| FY2017 | Dec 31, 2016 | $652.70M | Feb 28, 2018 |
| FY2017 | Dec 31, 2015 | $313.60M | Feb 28, 2018 |
| FY2017 | Dec 31, 2014 | $326.10M | Feb 28, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $938.50M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $927.30M | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $1.25B | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $2.56B | Mar 8, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 12, 2026 |
| FY2023 | Dec 31, 2023 | 0 | Mar 8, 2024 |
| FY2023 | Aug 12, 2023 | 17 | Mar 8, 2024 |
| FY2025 | Aug 11, 2023 | 17 | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | (7) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Mar 8, 2024 |
| FY2018 | Dec 31, 2018 | (1) | Mar 1, 2019 |
| FY2018 | Sep 30, 2018 | (3) | Mar 1, 2019 |
| FY2018 | Jun 30, 2018 | (1) | Mar 1, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 12, 2026 |
| FY2023 | Dec 31, 2023 | 0 | Mar 8, 2024 |
| FY2023 | Aug 12, 2023 | 16 | Mar 8, 2024 |
| FY2025 | Aug 11, 2023 | 16 | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | (7) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | (3) | Mar 16, 2023 |
| FY2018 | Dec 31, 2018 | (1) | Mar 1, 2019 |
| FY2018 | Sep 30, 2018 | (3) | Mar 1, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 35.38M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 37.58M | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | 37.57M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | 79.10M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | 78.35M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | 77.68M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | 76.81M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | 76.17M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | 75.56M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | 75.14M | Feb 28, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $0 | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | $0 | Mar 1, 2021 |
| FY2020 | Dec 31, 2018 | $7.70M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $30.60M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $64.60M | Mar 1, 2019 |
| FY2017 | Dec 31, 2015 | $75.60M | Feb 28, 2018 |
| FY2016 | Dec 31, 2014 | $74.90M | Feb 24, 2017 |
| FY2015 | Dec 31, 2013 | $74.00M | Feb 29, 2016 |
| FY2014 | Dec 31, 2012 | $72.83M | Feb 17, 2015 |
| FY2013 | Dec 31, 2011 | $72.90M | Mar 3, 2014 |